Lirulimab, a mAb that blocks KIR2DL1 and KIR2DL2/L3, has been developed as an NK therapeutic and tested in human clinical trials to treat solid tumors and hematologic malignancies (35); it could potentially be repositioned to alter T cell lifespan. This evidence concerns the gene KIR2DL1 and hematologic disorder.